[Colossal in Forbes] Biotech companies are ripe for machine learning adoption

We are at the infancy of the biotech industry’s adoption of machine learning tools. But, over the next 20 years, a more “multidisciplinary and data-intensive approach to life sciences will shift our understanding of and ability to manipulate living matter.” However, lack of data sophistication is limiting the potential for rapid advancement right now. And, in my opinion, the more we wait, the more we will fall behind.

Read more here.